TT-OAD2 free base

Cat. No.: HY-129658: FAQs
Data Sheet Handling Instructions

Molarity Calculator

TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.

For research use only. We do not sell to patients.

TT-OAD2 free base Chemical Structure

CAS No. : 1246826-07-2

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of TT-OAD2 free base:

TT-OAD2 Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment^[1]^[2].

IC₅₀ & Target

EC50: 5 nM (GLP-1 receptor)^[2]

In Vitro

TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests^[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection (Single dose)
Result:	Induced plasma insulin.

Molecular Weight

856.83

Formula

C₅₀H₄₇Cl₂N₃O₆

CAS No.

1246826-07-2

SMILES

O=C(O)[C@H](CC1=CC=C(C2=C(C)C(C)=NC=C2)C=C1)NC([C@H]3N([C@H](C4=CC=CC=C4)CC)CC5=C(C=C(OC[C@H](C6=CC=C(OCC7=CC=C(Cl)C(Cl)=C7)C=C6)O8)C8=C5)C3)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436. [Content Brief]

[2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

TT-OAD2 free base Related Classifications

Metabolic Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TT-OAD21246826-07-2GCGRGlucagon ReceptorGLP-1diabetesobesityG-protein-couplednon-peptideinsulinotropiccAMPcalciumpERK1/2β-arrestinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks